Identification of Novel Potential Herbal Drug Targets against Beta-Catenin in the Treatment of Oral Squamous Cell Carcinoma
Open Access
- 1 December 2024
- journal article
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 25 (12) , 4181-4188
Abstract
Objective: The study aims to identify potential pharmacophore models for targeting beta-catenin, a crucial protein involved in the development of oral squamous cell carcinoma (OSCC), using a combination of herbal compounds and computational approaches. Methods: Five natural compounds namely Quercetin, Lycopene, Ovatodiolide, Karsil, and Delphinidin were selected based on their reported activity against beta-catenin. Ligand characteristics were analyzed using SwissADME to evaluate drug-likeness, lipophilicity (logP), and bioavailability. The three-dimensional structure of beta-catenin was retrieved from the Protein Data Bank (PDB). Pharmacophore modeling was performed using Pharmagist software, followed by molecular docking using Swissdock to assess binding interactions and energies. Results: Out of thousands of pharmacophore hits generated, 23 were selected based on drug-likeness properties. Molecular docking revealed that ZINC94512303, derived from the combination of the selected herbal compounds, exhibited the highest binding energy of -8.91 kcal/mol with beta-catenin, outperforming individual herbal compounds. This compound adhered to all drug-likeness rules and demonstrated optimal pharmacokinetic properties. Conclusion: The identified pharmacophore, ZINC94512303, shows promise as a therapeutic agent targeting beta-catenin in OSCC. The combination of computational drug design with herbal compounds offers a novel approach to enhance the efficacy of cancer treatment. Further pharmacokinetic and pharmacodynamic studies, along with in vitro and clinical evaluations, are recommended to validate the therapeutic potential of this compound.Keywords
This publication has 30 references indexed in Scilit:
- Is β-Catenin a Druggable Target for Cancer Therapy?Trends in Biochemical Sciences, 2018
- In vitro and in vivo anti-cancer activity of silymarin on oral cancerTumor Biology, 2018
- Wnt/beta-catenin pathway: modulating anticancer immune responseJournal of Hematology & Oncology, 2017
- SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small moleculesScientific Reports, 2017
- Anticancer and apoptosis-inducing effects of quercetin in vitro and in vivoOncology Reports, 2017
- Delphinidin, a major anthocyanin, inhibits 3T3‐L1 pre‐adipocyte differentiation through activation of Wnt/β‐catenin signalingBioFactors, 2016
- Natural Products as a Vital Source for the Discovery of Cancer Chemotherapeutic and Chemopreventive AgentsMedical Principles and Practice, 2015
- Silibinin inhibits Wnt/β-catenin signaling by suppressing Wnt co-receptor LRP6 expression in human prostate and breast cancer cellsCellular Signalling, 2012
- E‐Cadherin/β‐Catenin Complex and the Epithelial BarrierBioMed Research International, 2011
- Deterministic Pharmacophore Detection via Multiple Flexible Alignment of Drug-Like MoleculesJournal of Computational Biology, 2008